CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Grant or award Chief R&D Officer acquired 205,150 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Director sold 49,933 shares at $10.11 ($504,823)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Legal Officer sold 150,000 shares at $9.15 ($1,372,500)
- 144 Insider Sale of Securities
- 4 Grant or award Director acquired 528 shares (grant or award)
- 4 Returned to the company Director returned 305,995 shares (to the company)
- 4 Grant or award Director acquired 848 shares (grant or award)
- 4 Grant or award Director acquired 1,285 shares (grant or award)
- 4 Grant or award Director acquired 642 shares (grant or award)
- 144 Insider Sale of Securities
- 10-K Report Annual Report
- 8-K Event Results of operations · Regulation FD disclosure
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Grant or award Director acquired 14,854 shares (grant or award)
Page 3 of 99 · 1,967 filings